Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02191930 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (NCT02191930)

Trial Description
The purpose of this trial is to determine:

  • Objective response rate (ORR), defined as the proportion of patients having CR, CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy
  • Progression-free survival (PFS) 3 years after registration

This trial is sponsored by University of Cologne. [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 70
  • Start: September 2014
  • Estimated Primary Completion: September 2015
  • Last verified: July 2014

Click here for an overview of other trials with brentuximab vedotion.

Study Schematic

NCT02191930 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar